Gossamer Bio adds Greg Ciongoli to board and audit committee
The seralutinib developer named the Adiumentum Capital founder as a Class III director effective September 16, 2026.
SEC filing
Latest
3 stories
Wednesday, September 16
Wednesday, August 12
Atara reports FDA meeting progress on tabelecleucel BLA resubmission, trims costs
Atara said it met with FDA on a path to resubmit the tabelecleucel BLA using existing Phase 3 data, while cutting quarterly costs 87% year over year.
SEC filing
Thursday, July 23
ImageneBio names Yanina Grant-Huerta as CFO, effective July 20, 2026
The company also disclosed that Chief Medical Officer Benjamin Porter-Brown will shift to a consulting role starting July 24, 2026.
SEC filing